{"id":"tp-56042","type":"article-newspaper","title":"Immix Biopharma Reports $340.9 Million in Cash, Cash Equivalents and Marketable Securities","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/56042","datePublished":"2026-11-12T23:33:28.000Z","dateModified":"2026-11-12T23:33:28.000Z","language":"en","abstract":"The company expects the balance at quarter-end to fund operations into mid-2028. Third-quarter operating expenses were $15.9 million.","section":"Business","references":[]}